ϟ
ISSN: 1617-58911439-0930

Deutsche Zeitschrift für Onkologie (2001. Internet)

Publisher: Georg Thieme Verlag KG

Deutsche Zeitschrift für Onkologie (2001. Internet) is a journal published by Georg Thieme Verlag KG.You can read and download all the PDFs for the journal Deutsche Zeitschrift für Onkologie (2001. Internet) here on OA.mg

DOI: 10.1055/s-2006-932318
2006
Neue Wege der Prävention von Darm-Neoplasien
Harald Hoensch, Wilhelm Kirch
DOI: 10.1055/s-2007-968116
2007
Zytostatika und Mikronährstoffe - Medikationsorientierte Supplementierung
Uwe Gröber
DOI: 10.1055/s-2006-932349
2006
Eine adäquate Aufklärung des Patienten vor einer PSA-Bestimmung ist von essentieller Bedeutung
Bernd Schmitz-Dräger
DOI: 10.1055/s-2000-11215
2000
Therapeutische Tumorvakzination - Eine Standortbestimmung -
Kurt Schumacher
DOI: 10.1055/s-2006-952102
2006
Praktische Aspekte der Schmerztherapie in der Palliation von Krebskranken
Hans-Hermann Nägelein
DOI: 10.1055/s-2006-932317
2006
Gesundheitserziehung ist genau so wichtig wie lesen, schreiben und rechnen zu lernen
Kurt S. Zänker
DOI: 10.1055/s-2007-968072
2007
Neue Substanzen in der medikamentösen Therapie des nicht-kleinzelligen Lungenkarzinoms (NSCLC)
Christian Manegold
In the last years, there has been a significant recognition in the application of drugs in the therapy of non-small cell bronchial carcinoma (NSCLC). The development of cytostatic therapy is decisively influenced and accelerated by new cytostatic substances including; gemcitabine, docetaxel, paclitaxel, vinorelbine and pemetrexed. Through “targeted therapy”, further improvement in drug therapy is expected from new substances. Examples include the new development of EGFR tyrosin-kinase inhibitor, erlotinib as well as multi-tyrosin-kinase inhibitors, ZD6474, sorafinib and sunitinib. The monoclonal antibodies cetuximab and bevacizumab are also significantly important. There is recent evidence of the application of bevacizumab on selected patients with advanced NSCLC. The patients' survival time was significantly elongated by the supplementation of bevacizumab to the standard chemotherapy. Currently, several immunotherapeutic strategies and the bisphosphonates in NSCLC are being clinically tested in phase III studies.
DOI: 10.1055/s-2004-834435
2004
Cited 4 times
Pulsierende Magnetfeldtherapie bei zytostatisch bedingter Polyneuropathie
Manfred Gabrys
DOI: 10.1055/s-2006-932348
2006
Bedeutung des Prostata-spezifischen Antigens (PSA) für Diagnostik und Therapie des Prostatakarzinoms
Oliver Hakenberg
DOI: 10.1055/s-2005-862592
2005
Retrospektive Untersuchung zur Therapie mit Mistelextrakten bei Mammakarzinom
C. Stumpf, S. Rieger, M. Schietzel
DOI: 10.1055/s-2008-1044038
2008
Krebs und Telomere
Oliver Zschenker, John P. Murnane
In general, cancer cells have shorter telomeres than normal somatic cells. However, compared to normal cells, they use reactivation of telomerase or other mechanisms to maintain telomere length and in consequence to bypass cell death. New results indicate that telomere biology might be a good tool for the fight against cancer in the future by disturbing or influencing these mechanisms.
DOI: 10.1055/s-0029-1213514
2009
Tumorimmunologie und therapeutische immunologische Strategien in der Onkologie
Niels Halama, Inka Zörnig, Dirk Jäger
The interaction between the immune system and malignant cells is a key element of research in oncology. The influence of the tumor-directed immune response on prognosis and the clinical course in tumor patients has become clearer recently. Shaping or modulating the immune response has become an integral part of treatment concepts in oncology. The underlying mechanisms in the regulation of the immune system are of high complexity. This complexity gives rise to a variety of different treatment approaches. Treatment strategies include the administration of antibodies, immunomodulatory strategies and T cell based therapies. Within this review the current concepts and future perspectives in understanding and modulating the immune system in the treatment of cancer are discussed.